ClinConnect ClinConnect Logo
Search / Trial NCT01066208

American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) Diagnostic and Classification Criteria for Primary Systemic Vasculitis

Launched by UNIVERSITY OF OXFORD · Feb 9, 2010

Trial Information

Current as of July 21, 2025

Unknown status

Keywords

Classification Criteria Diagnostic Criteria

ClinConnect Summary

The systemic vasculitides are a group of uncommon but important diseases whose prognosis has improved dramatically with the use of immunosuppressive therapy. However, long-term morbidity from recurrent disease flares, low-grade grumbling disease and/or accumulating damage from previous disease activity or drug therapy now characterise the long-term outlook for patients with vasculitis. There remains major controversy, and incompatibility between the ANCA-associated vasculitides: granulomatosis with polyangiitis (Wegener's), microscopic polyangiitis, and Churg Strauss Syndrome, as well as po...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria for Classification criteria:
  • 1. Adult patients aged \>18 years. There is no upper age limit.
  • 2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
  • 3. Presumed diagnosis of a primary systemic vasculitis.
  • Exclusion criteria for classification criteria:
  • 1. Patients \< 18 years of age.
  • 2. Inability to provide informed consent.
  • 3. Hepatitis B or C
  • 4. Co-morbidities that explain the clinical symptoms and signs on which the diagnosis of vasculitis is made. E.g. infection, tumour, other inflammatory condition, etc.
  • Inclusion criteria for diagnostic criteria:
  • 1. Adult patients aged \>18 years. There is no upper age limit.
  • 2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
  • 3. Suspected diagnosis of a primary systemic vasculitis
  • Inclusion criteria for controls group for diagnostic criteria:
  • 1. Adult patients aged \>18 years. There is no upper age limit.
  • 2. Ability to give informed consent. If the patient is unable to give informed consent as a result of death or physical incapacity, then informed assent from next of kin.
  • 3. Patients presenting to secondary care with one of the following clinical presentations: I.Multi-system disease. Presentation of disease with at least 2 organs involved. II.Pulmonary-renal syndrome. Defined as haemoptysis / pulmonary haemorrhage with acute renal impairment. III.Acute renal failure IV.Acute respiratory distress. V.Chronic upper airways symptoms and signs. VI.Inflammatory polyarthritis. VII.Fever of unknown origin. VIII.Acute or chronic abdominal pain IX.Hypertension. X.Referred to secondary care with suspicion of vasculitis but confirmed not to have vasculitis. XII.New onset headache. XIII.Jaw or tongue pain. XIV.Sudden visual loss. XV.Limb claudication. XVI.Aortic aneurysm \>5cm.
  • Exclusion Criteria for diagnostic criteria:
  • 1. Patients under the age of 18
  • 2. Patient or next of kin unable or unwilling to provide informed consent or assent.

About University Of Oxford

The University of Oxford, a prestigious institution renowned for its excellence in research and education, serves as a leading clinical trial sponsor dedicated to advancing medical science and improving patient care. With a rich history of innovation and a multidisciplinary approach, the university leverages its extensive expertise in various fields, including medicine, public health, and biomedical research, to conduct rigorous clinical trials. Collaborating with healthcare professionals, industry partners, and regulatory bodies, the University of Oxford aims to translate groundbreaking research findings into effective therapies and interventions, contributing to the global effort of enhancing health outcomes.

Locations

Rochester, Minnesota, United States

Philadelphia, Pennsylvania, United States

Birmingham, Alabama, United States

San Francisco, California, United States

Baltimore, Maryland, United States

Pittsburgh, Pennsylvania, United States

Aberdeen, Scotland, United Kingdom

Uppsala, , Sweden

Cork, , Ireland

Pittsburgh, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Birmingham, Alabama, United States

Chapel Hill, North Carolina, United States

Cleveland, Ohio, United States

Herston, Queensland, Australia

Uppsala, , Sweden

Parma, , Italy

Norwich, , United Kingdom

Innsbruck, , Austria

Philadelphia, Pennsylvania, United States

Auckland, , New Zealand

Basel, , Switzerland

Helsinki, , Finland

Oxford, , United Kingdom

Okayama, , Japan

Amsterdam, , Netherlands

Leuven, , Belgium

Copenhagen, , Denmark

Osaka, , Japan

Münster, , Germany

Ankara, , Turkey

Romford, Essex, United Kingdom

Seoul, , Korea, Republic Of

Cambridge, , United Kingdom

Kanazawa, Ishikawa, Japan

Norwich, Norfolk, United Kingdom

Kagawa, , Japan

Chiba, , Japan

Winnipeg, Manitoba, Canada

Ipswich, Suffolk, United Kingdom

Hamilton, , New Zealand

Calgary, , Canada

Southampton, , United Kingdom

Reggio Emilia, , Italy

Jena, , Germany

Kristiansand, , Norway

Prague, , Czech Republic

Groningen, , Netherlands

Calgary, Alberta, Canada

Cleveland, Ohio, United States

Helsinki, , Finland

Chapel Hill, North Carolina, United States

Los Angeles, California, United States

San Francisco, California, United States

Boston, Massachusetts, United States

Ann Arbor, Michigan, United States

Lebanon, New Hampshire, United States

New York, New York, United States

Salt Lake City, Utah, United States

San Fernando Del Valle De Catamarca, Catamarca, Argentina

Buenos Aires, , Argentina

Canberra, Australian Capital Territory, Australia

Hamilton, Ontario, Canada

Ottawa, Ontario, Canada

Toronto, Ontario, Canada

Montreal, Quebec, Canada

Sherbrooke, Quebec, Canada

Ontario, , Canada

Beijing, , China

Prague, , Czech Republic

Assiut, , Egypt

Cairo, , Egypt

Paris, , France

Luebeck, , Germany

Plochingen, , Germany

Tübingen, , Germany

Debrecen, , Hungary

Lucknow, Uttar Pradesh, India

Chandigarh, , India

Hyderabad, , India

New Delhi, , India

Vellore, , India

Dublin 4, , Ireland

Reggio Emilia, , Italy

Kamogawa City, Chiba Prefecture, Japan

Tsukuba, Ibaraki Prefecture, Japan

Miyazaki City, Miyazaki Prefecture, Japan

Kawagoe, Saitama Prefecture, Japan

Mitaka, Tokyo Prefecture, Japan

Kanagawa, , Japan

Kanazawa, , Japan

Saitama, , Japan

Tochigi Ken, , Japan

Tokyo, , Japan

Mexico City, , Mexico

Mexico City, , Mexico

Amsterdam, , Netherlands

Groningen, , Netherlands

Christchurch, Canterbury, New Zealand

Auckland, , New Zealand

Tromsø, , Norway

Kraków, , Poland

Almada, , Portugal

Lisbon, , Portugal

Porto, , Portugal

Moscow, , Russian Federation

Ljubljana, , Slovenia

Barcelona, Catalonia, Spain

Columbo 8, , Sri Lanka

Lund, , Sweden

Stockholm, , Sweden

Stockholm, , Sweden

Umeå, , Sweden

Zurich, , Switzerland

Istanbul, , Turkey

Istanbul, , Turkey

Istanbul, , Turkey

Istanbul, , Turkey

Istanbul, , Turkey

Carlisle, Cumbria, United Kingdom

Basildon, Essex, United Kingdom

Westcliff On Sea, Essex, United Kingdom

Kirkcaldy, Fife, United Kingdom

Glasgow, Scotland, United Kingdom

Carshalton, Surrey, United Kingdom

Birmingham, , United Kingdom

Dudley, , United Kingdom

London, , United Kingdom

Manchester, , United Kingdom

Nottingham, , United Kingdom

Oxford, , United Kingdom

Reading, , United Kingdom

Slough, , United Kingdom

York, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Raashid A Luqmani, DM, FRCP(E)

Principal Investigator

University of Oxford, United Kingdom

Peter Merkel, MD, MPH

Principal Investigator

University of Pennsylvania

Richard Watts, DM, FRCP

Principal Investigator

University of East Anglia

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials